Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | ECE1 | P42892 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28988576 | 0.87 | BCL2L1 (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL18652677 | 0.86 | KDM4E (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL319496 | 0.82 | MGAM (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1722822 | 0.82 | KMO (0.54) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31086447 | 0.80 | MCL1 (0.57) | P4HTMDHODHNR4A2NPC1RAB9A | |
| SCHEMBL29254808 | 0.80 | MCL1 (0.57) | P4HTMDHODHNR4A2NPC1RAB9A | |
| SCHEMBL29533318 | 0.80 | KDM4E (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL318608 | 0.80 | KDM4E (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2837730 | 0.79 | KDM4E (0.54) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL319233 | 0.79 | PTGS2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878983-B2 | Process for fluorinating compounds | DOW AGROSCIENCES LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170066721-A1 | PROCESS FOR FLUORINATING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-03-09 | — | — | US | disclosed |
| US-20170066721-A1 | PROCESS FOR FLUORINATING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-03-09 | — | — | US | disclosed |
| CN-105899488-A | Process for fluorinating compounds | 美国陶氏益农公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| CN-103080106-A | Cyclic ether compounds useful as kinase inhibitors | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066721-A1 | PROCESS FOR FLUORINATING COMPOUNDS | NEU4, NMBR, SNRPF | KDM4E 307/4885ALOX15 4187/4885TSHR 269/4885 |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | KDM4E 636/4885ALOX15 4473/4885TSHR 4240/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | KDM4E 946/4885ALOX15 4796/4885TSHR 2328/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | KDM4E 946/4885ALOX15 4796/4885TSHR 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.